Navigation Links
ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
Date:4/1/2008

LEUVEN, Belgium, April 1 /PRNewswire-FirstCall/ --

- Trial Results Expected Mid-2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular diseases, eye diseases and cancer, today announces that it has completed patient enrolment for its Phase IIb MIVI III trial in the United States. This study is designed to evaluate the safety and efficacy of Microplasmin in vitrectomy (MIVI III - Microplasmin for Vitreous Injection).

A vitrectomy is a surgical procedure carried out in the treatment of many back of the eye diseases such as retinal detachment, diabectic vitreous hemorrhage and macular hole. Vitrectomy is used to induce a posterior vitreous detachment (PVD) which involves removing the vitreous via suction. Microplasmin is a proteolytic enzyme that cleaves important molecules which link the vitreous to the retina and therefore has the potential to facilitate vitrectomy and induce PVD without the risks inherent in detachment by surgical intervention.

MIVI III is a Phase IIb, randomized, double-masked, placebo-controlled, dose-ranging trial evaluating three doses of Microplasmin (25, 75 and 125 μg) versus placebo in 120 patients scheduled for vitrectomy. The trial is taking place across 19 sites throughout the United States and is assessing the safety and efficacy of Microplasmin intravitreal injection 7 days prior to vitrectomy. Top-line, unmasked results of this trial are expected in June 2008.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on today's announcement, said: "We are very pleased to have completed enrolment in our lead program. Microplasmin has the potential to significantly change the way we treat back of the eye diseases and this study will bring us a step closer to realising this potential. Due to encouraging safety and efficacy results obtained from both the MIVI I and MIVI II Traction Phase II trials which were conducted in Europe, we are confident that
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
2. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
3. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
4. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
5. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
6. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
7. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
8. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
9. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
10. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
11. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... May 26, 2015  Organovo Holdings, Inc. (NYSE MKT: ... breakthrough 3D bioprinting technology, announced today that the company ... 2015 Healthcare Conference, to be held in ... Keith Murphy , Chairman and Chief Executive Officer, ... advances and partnerships. Details of the presentations ...
(Date:5/26/2015)... May 26, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that the Company,s President and ... present at the Jefferies 2015 Global Healthcare ... 11:30 a.m. EDT. Dr. Cauwenbergh will present ...
(Date:5/26/2015)... May 26, 2015 For the ... Quality of Life Throughout Europe, the Middle ... Astellas Pharma EMEA is celebrating its 10 ... through the historic merger of Japanese pharmaceutical companies Yamanouchi ... committed to turning science into value for patients through ...
Breaking Medicine Technology:Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 2Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 2RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 4Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4
... symptoms of ADHD, DURHAM, N.C., Sept. 10 ... stress has been shown to significantly reduce,symptoms of ... phase 3 clinical trial conducted by Addrenex,Pharmaceuticals., ... achieved statistically,significant improvement over placebo in reducing an ...
... combination of micronutrients superior to, current ,AREDS, standard ... -, HOUSTON, Sept. 10 A landmark ... a patented,combination of antioxidants and micronutrients, enabled patients ... in the study,s,placebo arm, who received the "AREDS-type" ...
Cached Medicine Technology:Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD 2Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD 3TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 2TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 3
(Date:5/26/2015)... 26, 2015 Abington is pleased ... a physician practice with seven medical professionals, has ... eighth primary-care site in the United States to ... home by the National Committee for Quality Assurance. ... preventative and sick care – including routine gynecology ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 Two ... recently joined Dr. Marissa Pei on a ... conversation focusing on addiction. Aired on KCAA AM 1050, ... Deena Duncan, marriage and family therapist, as they discuss ... estimated to affect more than 23.5 million Americans. The ...
(Date:5/26/2015)... May 26, 2015 CIO Review has chosen ... Promising Pharma and Life Sciences Technology Solution Providers. The positioning ... 11 compliant solution which is applicable across the entire security ... necessary for broad adoption. , “SIGNiX has been on ... the Pharma and Life Sciences Technology space, and we are ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week is ... by the Substance Abuse and Mental Health Services Administration ... action about, substance abuse as well as mental health ... to join in promoting prevention strategies, in educating other ... building community partnerships. , The Voice of One, the ...
(Date:5/26/2015)... Scientists at the University of Pennsylvania ... advanced mesothelioma patients benefit from immunotherapy; surgery may be ... on the new research. Click here to read ... thoracic surgery and pulmonology theorized that, because large mesothelioma ... attack, immunotherapy drugs might work better if the tumor ...
Breaking Medicine News(10 mins):Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2
... Nov. 12 Governor Jennifer M.,Granholm, Attorney General ... Barrett today kicked off the 4th Annual "Support ... raises funds to,support Michigan soldiers, sailors, and Marines ... benefit the Bob Woodruff Family,Fund founded by Michigan ...
... personalized portal for referring ... ... AMCS ),a leader in radiology and medical image and information management,solutions, ... that can help imaging businesses grow by attracting,referrals and securing referring ...
... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the ... both consumers and businesses, today announced that it,has ... will report results for its third quarter ended ... on Wednesday, November 14, 2007 and,will host a ...
... may be tied to weight , , MONDAY, Nov. 12 (HealthDay ... health problems, new research suggests that fat men are twice ... than men of normal weight. , The research doesn,t confirm ... death from prostate cancer, and it,s not clear if losing ...
... researchers have developed a small molecule that can turn the ... death signal. The molecule mimics the activity of Smac, a ... cells. ,The researchers say their findings suggest that Smac-mimetic ... and other cancers. Such therapy may be less toxic to ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
Cached Medicine News:Health News:Governor Granholm, Attorney General Cox, & Michigan Chamber Kick Off 4th Annual 'Support MI Troops' Fundraising Drive Proceeds to Benefit the Bob Woodruff Family Fund 2Health News:AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow 2Health News:AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow 3Health News:eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call 2Health News:Obesity Linked to Prostate Cancer Death Rates 2Health News:Obesity Linked to Prostate Cancer Death Rates 3Health News:Smac-ing lung cancer to death 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: